News
Active Startup: Kanyr Pharma
Published: 10 October 2019
Business Snapshot
Kanyr has proprietary data on their mechanism of action and a proprietary small molecule lead compound inhibitor allowing for the targeting of phosphatases of regenerating liver (PRLs) through a newly identified co-oncogenic partner.
Target Markets
Immunotherapy (cancer).
Intellectual Property
In prosecution in Canada, US, Europe, Japan, China.
Founder
Michel Tremblay